Source: WESTLAKE VILLAGE, Calif., Feb. 14, 2018 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced that the first patient has been dosed in the Company’s first-in-human, Phase 1/2 proof-of-concept clinical trial of topical product candidate SNA-125 in the treatment of psoriasis and the associated pruritus, or itch. SNA-125 is…...